Skip to main content

Table 1 Retrospective cohort: patient characteristics

From: Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data

Characteristics n. (%)
Total n. of patients 174 (100)
Sex  
 Male 80 (46)
 Female 94 (54)
Median age (range) 62 years (28–79)
ECOG Performance Status  
 0 106 (61)
 1 52 (30)
 2 16 (9)
Site of primary tumor  
 Intrahepatic 86 (49)
 Extrahepatic 37 (21)
 Gallbladder 34 (20)
 Ampullary 17 (10)
CA19.9 before second-line CT  
  < Median value (157 U/ml) 71 (41)
  ≥ Median value (157 U/ml) 83 (48)
 Data missing 20 (11)
Previous response to first-line CT  
 Partial response 37 (21.3)
 Stable disease 70 (40.3)
 Progressive disease 67 (38.4)
Median PFS to first-line CT 5.8 months
Third-line CT received 74 (43)
 Platinum plus or minus gemcitabine or fluoropyrimidine 24 (14)
 Irinotecan plus or minus 5-fluorouracil or capecitabine 17 (10)
 Monotherapy with 5-fluorouracil or capecitabine 10 (6)
 Monotherapy with paclitaxel or docetaxel 7 (4)
 Monotherapy with epirubicin 5 (3)
 Other regimens 11 (6)
  1. Abbreviations: n number, CT chemotherapy, PFS progression-free survival; platinum: cisplatin, oxaliplatin or carboplatin; other regimens: different combinations with fluoropyrimidines and other agents (taxanes, anthracyclines, gemcitabine)